SGLT2 Inhibitors and Cardiorenal Outcomes

  • 1 Brendon L. Neuen, MBBS(Hons), is a Clarendon Scholar at the Nuffield Department of Population Health, University of Oxford, UK. Edgar V. Lerma, MD, is clinical professor of medicine at the University of Illinois at Chicago College of Medicine. Joel Topf, MD, is Medical Director of St. Clair Nephrology Research in Roseville, MI.
Restricted access

Our top area to watch for 2019 is the advent of sodium glucose cotransporter 2 (SGLT2) inhibitors, oral anti-hyperglycemic agents that have been recently approved for the treatment of type 2 diabetes mellitus (T2DM).

Aside from their glucose-lowering effect, SGLT2 inhibitors have also been shown to reduce blood pressure, body weight, and albuminuria. These multiple beneficial metabolic effects have contributed, at least in part, to reductions in cardiovascular and renal outcomes observed in large cardiovascular outcome trials. As a result, the American Diabetes Association’s 2019 Standards of Medical Care in Diabetes (1) now recommends SGLT2 inhibitors as second-line